CD8A and glioblastoma: A Phase I/II study of combined DNX‐2401 with pembrolizumab, an anti‐PD‐1 antibody, in recurrent glioblastoma, revealed that in a few patients with a high objective response rate, a significant increase in immune infiltration of CD3+ and CD8 positive cells could be observed [76].